SCHEMBL6237432

SCHEMBL6237432

C#CCOCc1ccco1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.47
CYP3A4 P08684 1/20 0.47
ALOX15 P16050 1/20 0.47
GAA P10253 2/20 0.43
MAPT P10636 3/20 0.41
CYP2D6 P10635 1/20 0.41
MAOB P27338 1/20 0.39
SLC1A3 P43003 1/20 0.37
SLC1A2 P43004 1/20 0.37
SLC1A1 P43005 1/20 0.37
MAPK1 P28482 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
LMNA P02545 3/20 0.35
HTT P42858 3/20 0.35
KDM4E B2RXH2 2/20 0.35
CHRM2 P08172 1/20 0.34
POLB P06746 3/20 0.34
TSHR P16473 1/20 0.34
RECQL P46063 1/20 0.34
ESR2 Q92731 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL891457 0.81 ALDH1A1 (0.55) ALDH1A1CYP3A4ALOX15GAAMAPT
SCHEMBL6382888 0.81 ALDH1A1 (0.49) ALDH1A1GAAMAPTCYP2D6SLC1A3
SCHEMBL10485701 0.79 ALDH1A1 (0.53) ALDH1A1CYP3A4ALOX15GAAMAPT
SCHEMBL15087211 0.77 ALDH1A1 (0.52) ALDH1A1CYP3A4ALOX15GAAMAPT
SCHEMBL8440516 0.76
SCHEMBL1387211 0.75
SCHEMBL11749020 0.74 ALDH1A1 (0.57) ALDH1A1CYP3A4ALOX15GAAMAPT
SCHEMBL23902901 0.74 ALDH1A1 (0.48) ALDH1A1GAAMAPTCYP2D6SLC1A3
SCHEMBL15064216 0.74
SCHEMBL1152092 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022093792-A1 ELECTROLYTE ADDITIVES CONTAINING ONE, TWO, OR MORE TRIPLE-BONDED MOIETIES FOR SILICON ANODE-BASED BATTERIES ENEVATE CORPORATION (US) 2022-05-05 WO claimed
WO-2024180230-A1 5-METHYL-1,3-DIHYDROISOBENZOFURAN-4-OL PREPARED FROM 5-METHYLFURFURYL ALCOHOL AND PROPARGYL ALCOHOL DSM IP ASSETS B.V. (NL) 2024-09-06 WO disclosed
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 US disclosed
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 US disclosed
US-11539077-B2 Electrolyte additives containing one, two, or more triple-bonded moieties for silicon anode-based li-ion batteries ENEVATE CORPORATION (US) 2022-12-27 US disclosed
WO-2022093792-A1 ELECTROLYTE ADDITIVES CONTAINING ONE, TWO, OR MORE TRIPLE-BONDED MOIETIES FOR SILICON ANODE-BASED BATTERIES ENEVATE CORPORATION (US) 2022-05-05 WO disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 US disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 US disclosed
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-12-14 US disclosed
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-12-14 US disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 WO disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 WO disclosed
US-20100143980-A1 SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF BALAGURUNATHAN KUBERAN 2010-06-10 US disclosed
US-20100143980-A1 SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF BALAGURUNATHAN KUBERAN 2010-06-10 US disclosed
US-20050258553-A1 Method for the organometallic production of organic intermediate products comprising carbon-heteroatom bonds achieved by the deprotonation of heteroatoms ARCHIMICA GMBH (DE) 2005-11-24 US disclosed
EP-1537125-A1 METHOD FOR THE ORGANOMETALLIC PRODUCTION OF ORGANIC INTERMEDIATE PRODUCTS COMPRISING CARBON-HETEROATOM BONDS ACHIEVED BY THE DEPROTONATION OF HETEROATOMS Clariant GmbH (DE) 2005-06-08 EP disclosed
WO-2004024737-A1 METHOD FOR THE ORGANOMETALLIC PRODUCTION OF ORGANIC INTERMEDIATE PRODUCTS COMPRISING CARBON-HETEROATOM BONDS ACHIEVED BY THE DEPROTONATION OF HETEROATOMS CLARIANT GMBH (DE) 2004-03-25 WO disclosed
JP-2002105069-A METHOD FOR PRODUCING PROPARGYLFURFURYL ALCOHOLS SUMITOMO CHEM CO LTD 2002-04-10 JP disclosed
CN-1104849-A Fuming, hot-vaporizing insecticide for killing flies, and method for killing flies with the same DAINPPON JOCHUGIKU CO LTD (JP) 1995-07-12 CN disclosed
US-4496767-A REARRANGEMENT, ESTERIFICATION AND REDUCTION OF A FURAN-CARBINOL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1985-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 ALDH1A1 1966/4885CYP3A4 943/4885ALOX15 4158/4885
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 ALDH1A1 1966/4885CYP3A4 943/4885ALOX15 4158/4885
US-20050258553-A1 Method for the organometallic production of organic intermediate products comprising carbon-heteroatom bonds achieved by the deprotonation of heteroatoms IGLV6-57, ICMT, INTS6 ALDH1A1 883/4885CYP3A4 94/4885ALOX15 1624/4885
US-20100143980-A1 SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF CSGALNACT1, ST3GAL3, FUT6 ALDH1A1 936/4885CYP3A4 1078/4885ALOX15 856/4885
US-11539077-B2 Electrolyte additives containing one, two, or more triple-bonded moieties for silicon anode-based li-ion batteries SELENOI, SIK1, SIK2 ALDH1A1 264/4885CYP3A4 4627/4885ALOX15 4535/4885
US-11197859-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 ALDH1A1 1966/4885CYP3A4 943/4885ALOX15 4158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.